- Conditions
- Alzheimers Disease
- Interventions
- No Intervention
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 80,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more
Condition Directory
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 9, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
388
Shown on this page
12
Current sort
Recently updated
Condition scope
Alzheimer's Disease
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 25–36 of 388 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Alzheimer Disease
- Interventions
- Low Dose Benfotiamine, High Dose Benfotiamine, Placebo
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
- Conditions
- Alzheimer's Disease
- Interventions
- GSK4527226, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 21
- States / cities
- San Diego, California • Lake Mary, Florida • Lake Worth, Florida + 16 more
- Conditions
- Alzheimer's Disease
- Interventions
- No Intervention
- Other
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 6,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Nutley, New Jersey
- Conditions
- Early-Onset Alzheimer Disease
- Interventions
- ALN-APP, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 2
- States / cities
- La Jolla, California • Indianapolis, Indiana
- Conditions
- Alzheimer's Disease and Related Dementia
- Interventions
- DERA Online Training Program
- Behavioral
- Lead sponsor
- George Mason University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
- Interventions
- Spectris™ AD - Active, Spectris™ AD - Sham
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 68
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
- Conditions
- Alzheimer's Disease
- Interventions
- Piromelatine 20 mg, Placebo
- Drug
- Lead sponsor
- Neurim Pharmaceuticals Ltd.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 32
- States / cities
- Costa Mesa, California • Long Beach, California • San Diego, California + 21 more
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Interventions
- AADvac1, Donanemab
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Interventions
- AADvac1, Tau2
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
- Conditions
- Delirium, Neurocognitive Disorders, Mild Cognitive Impairment, Alzheimer Disease, Aging, Family Support, Family Members, Caregiver Burden, Implementation Science, Patient Satisfaction
- Interventions
- HELP, FAM-HELP
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 1,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Orange, California • Portland, Maine • Ann Arbor, Michigan + 4 more
- Conditions
- Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.